These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2924375)

  • 41. Pharmacokinetics and cytotoxicity of B.3839, a molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, in a mouse model.
    Loadman PM; Bibby MC; Double JA; McElhinney RS
    Invest New Drugs; 1992 Aug; 10(3):149-58. PubMed ID: 1428724
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical pharmacokinetics and dose optimisation of carboplatin.
    Duffull SB; Robinson BA
    Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetic study of cystemustine, administered on a weekly schedule in cancer patients.
    Cellarier E; Terret C; Labarre P; Ouabdesselam R; Curé H; Marchenay C; Maurizis JC; Madelmont JC; Cholle P; Armand JP
    Ann Oncol; 2002 May; 13(5):760-9. PubMed ID: 12075746
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics and pharmacodynamics of nitrosourea fotemustine: a French cancer centre multicentric study.
    Iliadis A; Launay-Iliadis MC; Lucas C; Fety R; Lokiec F; Tranchand B; Milano G
    Eur J Cancer; 1996 Mar; 32A(3):455-60. PubMed ID: 8814692
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG; Balcerzak SP; Kraut EH
    Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro and in vivo responses of a panel of murine colon tumours to TCNU: a positive correlation.
    Phillips RM; Bibby MC; Double JA
    Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1365-71. PubMed ID: 3181258
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 48. TCNU in advanced renal cancer. Phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group.
    Van Oosterom AT; Droz JP; Fossa ST; Bono AV; Splinter TA; Verbaeys AJ; Keizer J; De Pauw M; Sylvester R
    Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1889-90. PubMed ID: 2632270
    [No Abstract]   [Full Text] [Related]  

  • 49. Plasma pharmacokinetics of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial.
    Kestell P; Dunlop IC; McCrystal MR; Evans BD; Paxton JW; Gamage RS; Baguley BC
    Cancer Chemother Pharmacol; 1999; 44(1):45-50. PubMed ID: 10367748
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of a novel taurine nitrosourea, 1-(2-chloroethyl)-3-[2-(dimethylaminosulfonyl)ethyl]-1-nitrosour ea (TCNU) on cytotoxicity, DNA crosslinking and glutathione reductase in lung carcinoma cell lines.
    Tew KD; Dean SW; Gibson NW
    Cancer Chemother Pharmacol; 1987; 19(4):291-5. PubMed ID: 2954712
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized phase II trial of TCNU versus mitozolomide in malignant melanoma. EORTC Early Clinical Trials Group.
    Smyth JF; Gundersen S; Renard J; Pinedo HM
    Eur J Cancer Clin Oncol; 1989 Apr; 25(4):755-7. PubMed ID: 2714350
    [No Abstract]   [Full Text] [Related]  

  • 52. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
    Dhodapkar M; Rubin J; Reid JM; Burch PA; Pitot HC; Buckner JC; Ames MM; Suman VJ
    Clin Cancer Res; 1997 Jul; 3(7):1093-100. PubMed ID: 9815788
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration.
    McKeage MJ; Mistry P; Ward J; Boxall FE; Loh S; O'Neill C; Ellis P; Kelland LR; Morgan SE; Murrer B
    Cancer Chemother Pharmacol; 1995; 36(6):451-8. PubMed ID: 7554035
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancers.
    Zhou H; Choi L; Lau H; Bruntsch U; Vries EE; Eckhardt G; Oosterom AT; Verweij J; Schran H; Barbet N; Linnartz R; Capdeville R
    J Clin Pharmacol; 2000 Mar; 40(3):275-83. PubMed ID: 10709156
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Second-line chemotherapy with tauromustine in metastatic breast cancer in postmenopausal women: a phase II study.
    Ernst P; Balslev I; Mouridsen HT
    Cancer Treat Rep; 1987 Oct; 71(10):987-8. PubMed ID: 3652062
    [No Abstract]   [Full Text] [Related]  

  • 56. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
    Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ
    Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of navelbine after oral administration in cancer patients.
    Zhou XJ; Boré P; Monjanel S; Sahnoun Z; Favre R; Durand A; Rahmani R
    Cancer Chemother Pharmacol; 1991; 29(1):66-70. PubMed ID: 1742851
    [TBL] [Abstract][Full Text] [Related]  

  • 58. TCNU in colorectal cancer. How many patients are needed to demonstrate that a drug doesn't work?
    Wils J
    Ann Oncol; 1996 Feb; 7(2):211. PubMed ID: 8777181
    [No Abstract]   [Full Text] [Related]  

  • 59. Hepatic intra-arterial infusion of fotemustine: pharmacokinetics.
    Fety R; Lucas C; Solere P; Cour V; Vignoud J
    Cancer Chemother Pharmacol; 1992; 31(2):118-22. PubMed ID: 1451232
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II study of tauromustine in disseminated malignant melanoma.
    Gjedde SB; Mouridsen HT; L-Madsen E; Jensen NV; Blomquist E; Bergh J; Söderberg M; Wählby S
    Eur J Cancer; 1994; 30A(4):566. PubMed ID: 8018421
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.